Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Gemcitabine + PD-1 Inhibitor in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07902713Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07902713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902713.